Trial Profile
A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms With AZD8529 in Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs AZD 8529 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Biomarker; Therapeutic Use
- 31 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 31 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.